1 U.S. lawmaker has disclosed 1 Coherus BioSciences, Inc. trade under the STOCK Act — 0 buys and 1 sell in 2023. Congress has been net sellers of CHRS.
*Notional-weighted price return on lawmakers' disclosed buys of CHRS, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2023-01-23 | Shri Thanedar | SELL | $15K–$50K | $9.18 | $1.14 2026-08-13 | +87.6% exit |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
1 member of the U.S. House and Senate has disclosed Coherus BioSciences, Inc. transactions under the STOCK Act — 0 purchases and 1 sale. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a CHRS purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Every CHRS trade is marked to the latest close in the Return column; sells matched to a prior buy show a realized round-trip return.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded CHRS and how it performed.